Vivesto

Vivesto recently announced that the first patient has been dosed in the company's open-label, pilot clinical trial with Paccal Vet (paclitaxel micellar) in dogs with splenic hemangiosarcoma following splenectomy. An interim analysis is expected by the end of 2024.

The purpose of the event is to describe the increasing medical need for more veterinary oncology drugs and to present the ongoing clinical program with Paccal Vet and the regulatory pathway to a market-approved drug.

External speakers include Henrik Rönnberg, Professor in veterinary pharmacology at the Swedish University of Agricultural Sciences (SLU) in Uppsala, and Jim Perry, CEO of CASTR Alliance – the contract research organization (CRO) that is coordinating the study at the participating clinics in the United States. Vivesto's CEO Erik Kinnman, Chief Medical Officer Heidi B. Ramstad and Chief Regulatory Officer Johanna Röstin will also participate.

The presentations will be followed by a Q&A session where questions can be submitted in advance via info@vivesto.com

The presentations will be held in English and can be followed via https://www.finwire.tv/webcast/vivesto/paccalvet/ and will also be available afterwards on Vivesto's website. No registration is required.

Program:

• Introduction – Erik Kinnman
• Medical need – Henrik Rönnberg
• Paccal Vet pilot clinical trial – Heidi B. Ramstad 
• Clinical operations – CASTR Alliance
• Regulatory pathway to market approval – Johanna Röstin
• Q&A

About Paccal Vet
Vivesto's drug candidate Paccal Vet consists of paclitaxel formulated with the company's proprietary XR-17 technology. Vivesto has previously shown good safety of Paccal Vet in the treatment of various types of cancer in dogs. The absence of the solvent cremophor, to which dogs are particularly sensitive, may reduce the risk of serious side effects and death associated to the treatment. Paccal Vet also does not require the addition of human albumin, which when used in dogs can cause hypersensitivity reactions and reduced treatment effectiveness.

Previous clinical studies performed by Vivesto has demonstrated safety in more than 300 dogs. Also, anti-tumor activity has been shown in squamous cell carcinoma and non-resectable mammary carcinoma of stage III-V.

For more information:
Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com

About Vivesto AB
Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy.

Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.